Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA targeting KIFC1
- Development stage
- Preclinical
- Lead developer
- University of Tokyo
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
siRNA targeting KIFC1 is a therapeutic modality designed to silence the expression of Kinesin Family Member C1 (KIFC1), also known as HSET. KIFC1 is a minus-end-directed microtubule motor protein that is non-essential for normal cells but critical for cancer cells with supernumerary centrosomes. These cancer cells rely on KIFC1 to cluster extra centrosomes into two poles during mitosis, avoiding lethal multipolar divisions. By utilizing small interfering RNA (siRNA) to degrade KIFC1 mRNA, the protein's function is inhibited, leading to centrosome declustering, multipolar spindle formation, anaphase catastrophe, and apoptosis. This approach is being investigated as a novel therapeutic strategy for cancers characterized by centrosome amplification and poor prognosis, such as small cell lung cancer (SCLC).
- Other names
- KIFC1 siRNAKIFC-1 siRNAKIFC 1 siRNAHSET siRNAsiRNA-KIFC1siRNA-KIFC-1siRNA-KIFC 1
02
Targets
KIFC1
Beyond the preview
Go deeper on siRNA targeting KIFC1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA targeting KIFC1.